JPRN-UMIN000012798已完成2 期
The safety and efficacy trial of nab-paclitaxel and trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer - The safety and efficacy trial of nab-paclitaxel and trastuzumab as neoadjuvant chemotherapy for HER2- positive breast cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Pregnant or lactating women 2) Invasive cancer after completion of therapy(less than 5years ) 3) Asynchronous bilateral breast cancer
研究者
相似试验
终止
1 期
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic HyperbilirubinemiaPancreatic NeoplasmsCholestasisNCT02267707Celgene1
已完成
2 期
A feasibility study of Nab-Paclitaxel followed by Anthracycline-based regimen as adjuvant chemotherapy for breast cancer.(SBCCSG-21)Primary breast cancerJPRN-UMIN000006084Saitama Breast Cancer Clinical Study Group(SBCCSG)30
招募中
2 期
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancerRefractory small-cell lung cancerJPRN-UMIN000015565Dokkyo Medical University22
已完成
2 期
Phase II pilot study of nab-paclitaxel in patients with metastatic or unresectable urothelial cancer previously treated with cisplatin-based chemotherapy.urothelial cancerJPRN-UMIN000015260Department of Urology, Saitama Medical Center, Saitama Medical University5
已完成
不适用
A phase II study of nab-paclitaxel for pretreated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012972Kanagawa Cancer Center30